Evidence map›Paper›PMID 27256085›Full record

Observational studyBMJ open2016

Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK.

Sylvia Taylor, Robert J Taylor, Roger L Lustig, Cynthia Schuck-Paim, François Haguinet, David J Webb, John Logie, Gonçalo Matias, Douglas M Fleming

Registry-linked trialOpen access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01706302 (Burden of Respiratory Syncytial Virus), which is not on this map. Cited by 53 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 3 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01706302 completednot on this map

Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom, 1995 to 2009

TypeobservationalSponsorGlaxoSmithKlineRan2012 to 2012Enrolled1ConditionsRespiratory Syncyctial Virus VaccinesArmsData collection
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sylvia TaylorGSK Vaccines, Wavre, Belgium.
Robert J TaylorSage Analytica, Bethesda, Maryland, USA.
Roger L LustigSage Analytica, Bethesda, Maryland, USA.
Cynthia Schuck-PaimSage Analytica, Bethesda, Maryland, USA.
François HaguinetGSK Vaccines, Wavre, Belgium.
David J WebbGSK Pharmaceuticals, Uxbridge, UK.
John LogieGSK Pharmaceuticals, Uxbridge, UK.
Gonçalo MatiasGSK Vaccines, Wavre, Belgium.
Douglas M FlemingFaculty of Health and Medical Sciences University of Surrey, Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.
GlaxoSmithKline (Belgium) · BEGW Pharmaceuticals (United Kingdom) · GBUniversity of Surrey · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe burden of respiratory syncytial virus (RSV) illness is not well characterised in primary care. We estimated the burden of disease attributable to RSV in children in the UK between 1995 and 2009.

designTime-series regression modelling.

settingA multiple linear regression model based on weekly viral surveillance (RSV and influenza, Public Health England), and controlled for non-specific seasonal drivers of disease, estimated the proportion of general practitioner (GP) episodes of care (counted as first visit in a series within 28 days; Clinical Practice Research Datalink, CPRD), hospitalisations (Hospital Episode Statistics, HES) and deaths (Office of National Statistics, ONS) attributable to RSV each season.

participantsChildren 0-17 years registered with a GP in CPRD, or with a respiratory disease outcome in the HES or ONS databases. PRIMARY OUTCOME MEASURES: RSV-attributable burden of GP episodes, hospitalisations and deaths due to respiratory disease by age. RSV-attributable burden associated with selected antibiotic prescriptions.

resultsRSV-attributable respiratory disease in the UK resulted in an estimated 450 158 GP episodes, 29 160 hospitalisations and 83 deaths per average season in children and adolescents, with the highest proportions in children <6 months of age (14 441/100 000 population, 4184/100 000 and 6/100 000, respectively). In an average season, there were an estimated 125 478 GP episodes for otitis media and 416 133 prescriptions for antibiotics attributable to RSV. More GP episodes, hospitalisations and deaths from respiratory disease were attributable to RSV than to influenza in children under 5 years.

conclusionsThe burden of RSV in children in the UK exceeds that of influenza. RSV in children and adolescents contributes substantially to GP office visits for a diverse range of illnesses, and was associated with an average 416 133 prescribed antibiotic courses per season. Effective antiviral treatments and preventive vaccines are urgently needed for the management of RSV infection in children. TRIAL REGISTRATION NUMBER: NCT01706302.

Indexed as

SeasonsAdolescentAge DistributionAnti-Bacterial AgentsChildChild, PreschoolCost of IllnessDatabases, FactualDrug PrescriptionsFemaleHospitalizationHumansIncidenceInfantInfant, NewbornLinear ModelsAnti-Bacterial AgentsChildrenMortalityOtitis MediaRespiratory syncytial virus

Identifiers

PMID27256085
PMCPMC4893852
OpenAlexW2416818866

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.